Graham Capital Management L.P. Grows Stock Position in Theravance Biopharma, Inc. (NASDAQ:TBPH)

Graham Capital Management L.P. grew its position in Theravance Biopharma, Inc. (NASDAQ:TBPH) by 18.2% during the 4th quarter, HoldingsChannel.com reports. The fund owned 36,364 shares of the biopharmaceutical company’s stock after buying an additional 5,608 shares during the quarter. Graham Capital Management L.P.’s holdings in Theravance Biopharma were worth $342,000 at the end of the most recent reporting period.

Several other hedge funds and other institutional investors have also made changes to their positions in TBPH. Aquatic Capital Management LLC purchased a new position in shares of Theravance Biopharma in the fourth quarter valued at approximately $25,000. KLP Kapitalforvaltning AS purchased a new position in Theravance Biopharma during the fourth quarter worth approximately $69,000. Teacher Retirement System of Texas purchased a new position in Theravance Biopharma during the fourth quarter worth approximately $103,000. ClearAlpha Technologies LP purchased a new position in Theravance Biopharma during the fourth quarter worth approximately $109,000. Finally, Tower Research Capital LLC TRC lifted its position in Theravance Biopharma by 142.8% during the fourth quarter. Tower Research Capital LLC TRC now owns 12,670 shares of the biopharmaceutical company’s stock worth $119,000 after buying an additional 7,452 shares in the last quarter. Hedge funds and other institutional investors own 99.10% of the company’s stock.

Theravance Biopharma Trading Up 0.7%

Shares of NASDAQ TBPH opened at $9.20 on Friday. Theravance Biopharma, Inc. has a twelve month low of $7.44 and a twelve month high of $10.90. The stock has a fifty day simple moving average of $9.16 and a 200-day simple moving average of $9.30. The stock has a market capitalization of $460.01 million, a PE ratio of -9.11 and a beta of -0.10.

Theravance Biopharma (NASDAQ:TBPH) last released its earnings results on Thursday, May 8th. The biopharmaceutical company reported ($0.27) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.16). The company had revenue of $15.39 million during the quarter, compared to analysts’ expectations of $28.08 million. Theravance Biopharma had a negative net margin of 78.18% and a negative return on equity of 24.79%. On average, equities analysts predict that Theravance Biopharma, Inc. will post -1.09 earnings per share for the current year.

Insider Activity at Theravance Biopharma

In other Theravance Biopharma news, SVP Rhonda Farnum sold 4,000 shares of Theravance Biopharma stock in a transaction dated Monday, April 21st. The stock was sold at an average price of $9.00, for a total transaction of $36,000.00. Following the completion of the sale, the senior vice president now directly owns 370,038 shares of the company’s stock, valued at $3,330,342. The trade was a 1.07% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 6.90% of the stock is currently owned by company insiders.

Analyst Ratings Changes

TBPH has been the topic of a number of analyst reports. StockNews.com upgraded Theravance Biopharma from a “hold” rating to a “buy” rating in a research report on Wednesday. HC Wainwright reiterated a “buy” rating and set a $15.00 price objective on shares of Theravance Biopharma in a research report on Tuesday, February 25th. Three investment analysts have rated the stock with a hold rating and two have assigned a buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $11.33.

About Theravance Biopharma

Theravance Biopharma, Inc is a diversified biopharmaceutical company primarily focused on the discovery, development and commercialization of organ-selective medicines. Its purpose is to pioneer a new generation of small molecule drugs designed to better meet patient needs. Its research is focused in the areas of inflammation and immunology.
In pursuit of its purpose, Theravance Biopharma applies insights and innovation at each stage of its business and utilizes its internal capabilities and those of partners around the world.